Finally, dependence of MYB expression on the activity of super-enhancers with strong bromodomain protein occupancy, suggests that use of BET bromodomain inhibitors may render potential anti-tumorigenic response in ACC [5]. Here, DNER is linked to adrenal cortex carcinoma.